The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users

Drug and Alcohol Dependence

Volumn 128, Issue 1-2, 2013, Pages 64-70

  Vandrey, Ryan ^a   Stitzer, Maxine L ^a   Mintzer, Miriam Z ^a   Huestis, Marilyn A ^b   Murray, Jeannie A ^a   Lee, Dayong ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Cannabis; Dronabinol; Marijuana; Pharmacotherapy; THC; Withdrawal

Indexed keywords

AMPHETAMINE; DRONABINOL; MORPHINE; PLACEBO;

ADULT; AGGRESSION; ALERTNESS; ANGER; ANXIETY; AROUSAL; ARTICLE; CANNABIS ADDICTION; CHILL; COGNITION; CONCENTRATION LOSS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; FLUSHING; HEADACHE; HEART RATE; HUMAN; IRRITABILITY; MAINTENANCE DRUG DOSE; MOOD; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; RESTLESSNESS; SIDE EFFECT; SLEEP DISORDER; SLEEP QUALITY; SLEEP TIME; STOMACH PAIN; TACHYCARDIA; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADOLESCENT; ADULT; CANNABIS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EATING; FEMALE; HEART RATE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; SLEEP; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL;

CANNABIS; CANNABIS SATIVA;

EID: 84872407887     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.08.001     Document Type: Article

References (50)

1. AIHW Alcohol and Other Drug Treatment Services in Australian Capital Territory 2006-07: Findings from the National Minimum Data Set 2008, Australian Institute of Health and Welfare, Sydney.
2. Beardsley P.M., Kelly T.H. Acute effects of cannabis on human behavior and central nervous system functions. The Health Effects of Cannabis 1999, 127-170. Centre for Addiction and Mental Health, Toronto. H. Kalant, W.A. Corrigall, W. Hall, R.G. Smart (Eds.).
3. Benyamina A., Lecacheux M., Blecha L., Reynaud M., Lukasiewcz M. Current state of phamacotherapy and psychotherapy in cannabis withdrawal and dependence. Exp. Rev. Neurother. 2008, 8:479-491.
4. Boyd S.J., Tashkin D.P., Huestis M.A., Heishman S.J., Dermand J.C., Simmons M.S., Gorelick D.A. Strategies for quitting among non-treatment-seeking marijuana users. Am. J. Addict. 2005, 14:35-42.
5. Buchhalter A.R., Acosta M.C., Evans S.E., Breland A.B., Eissenberg T. Tobacco abstinence symptom suppression: the role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. Addiction 2005, 100:550-559.
6. Budney A.J., Novy P., Hughes J.R. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999, 94:1311-1322.
7. Budney A.J., Hughes J.R., Moore B.A., Novy P.L. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch. Gen. Psychiatry 2001, 58:917-924.
8. Budney A.J., Moore B.A., Vandrey R.G., Hughes J.R. The time course and significance of cannabis withdrawal. J. Abnorm. Psychol. 2003, 112:393-402.
9. Budney A.J., Vandrey R.G., Hughes J.R., Moore B.A., Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007, 86:22-29.
10. Budney A.J., Vandrey R.G., Hughes J.R., Thostenson J.D., Bursac Z. Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J. Subst. Abuse Treat. 2008, 35:362-368.
11. Chait L.D., Zacny J.P. Reinforcing and subjective effects of oral delta-9-THC and smoked marijuana in humans. Psychopharmacology 1992, 107:255-262.
12. Chung T., Martin C.S., Cornelius J.R., Clark D.B. Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addiction 2008, 103:787-799.
13. Cornelius J.R., Chung T., Martin C., Wood D.S., Clark D.B. Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addict. Behav. 2008, 33:1500-1505.
14. Curran H.V., Brignell C., Fletcher S., Middleton P., Henry J. Cognitive and subjective dose-response effects of acute oral delta-9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 2002, 164:61-70.
15. ElSohly Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005, 78:539-548.
16. EMCDDA Annual Report on the State of the Drugs Problem 2008, European Monitoring Centre for Drugs and Drug Addiction, Lisbon.
17. Gevins A., Cutillo B. Spatiotemporal dynamics of component processes in human working memory. Electroencephalogr. Clin. Neurophysiol. 1993, 87:128-143.
18. Haertzen C.H., Hickey J.E. ARCI: measurement of euphoria and other drug effects. Methods for Assessing the Reinforcing Properties of Abused Drugs 1987, 489-524. Springer-Verlag, New York. M.A. Bozarth (Ed.).
19. Haney M., Comer S.D., Ward A.S., Foltin R.W., Fischman M.W. Abstinence symptoms following oral THC administration to humans. Psychopharmacology 1999, 14:385-394.
20. Haney M., Hart C.L., Vosburg S.K., Comer S.D., Reed S.C., Foltin R.W. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 2008, 197:157-168.
21. Haney M., Hart C.L., Vosburg S.K., Nasser J., Bennett A., Zubaran C., Foltin R.W. Marijuana withdrawal in humans: effects of oral THC or Divalproex. Neuropsychopharmacology 2004, 29:158-170.
22. Hart C.L., Haney M., Ward A.S., Fischman M.W., Foltin R.W. Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend. 2002, 67:301-309.
23. Hart C.L., Ward A.S., Haney M., Comer S.D., Foltin R.W., Fischman M.W. Comparison of smoked marijuana and oral delta-9-tetrahydrocannabinol in humans. Psychopharmacology 2002, 164:407-415.
24. Heishman S.J., Evans R.J., Singleton E.G., Levin K.H., Copersino M.L., Gorelick D.A. Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend. 2009, 102:35-40.
25. Hudziak J., Helzer J.E., Wetzel M.W., Kessel K.B., McBee B., Janca A., Przybeck P. The use of the DSM-III-R Checklist for initial diagnostic assessments. Compr. Psychiatry 1993, 34:375-383.
26. Jones R.T., Benowitz N., Bachman J. Clinical studies of cannabis tolerance and dependence. Ann. N. Y. Acad. Sci. 1976, 282:221-239.
27. Kamien J.B., Bickel W.K., Higgins S.T., Hughes J.R. The effects of delta-9-tetrahydrocannabinol on repeated acquisition and performance of response squences and on self-reports in humans. Behav. Pharmacol. 1994, 5:71-78.
28. Kirk J.M., DeWit H. Responses to oral delta-9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacol. Biochem. Behav. 1999, 63:137-142.
29. Kleykamp B.A., Griffiths R.R., Mintzer M.Z. Dose effects of triazolam and alcohol on cognitive performance in healthy volunteers. Exp. Clin. Psychopharmacol. 2010, 18:1-16.
30. Levin F.R., Kleber H.D. Use of dronabinol for cannabis dependence: two case reports and review. Am. J. Addict. 2008, 17:161-164.
31. Levin F.R., Mariani J.J., Brooks D.J., Pavlicova M., Cheng W., Nunes E.V. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011, 116:142-150.
32. Lowe R.H., Karschner E.L., Schwilke E.W., Barnes A.J., Huestis M.A. Simultaneous quantification of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J. Chromatogr. A 2007, 1163:318-327.
33. McClure E.A., Vandrey R., Johnson M.W., Stitzer M.L. Effects of varenicline on abstinence and smoking reward following a programmed lapse. Nicotine Tob. Res. 2012, (Epub ahead of print).
34. McLeod D.R., Griffiths R.R., Bigelow G.E., Yingling J. An automated version of the digit symbol substitution test (DSST). Behav. Res. Methods 1982, 14:463-466.
35. Mintzer M.Z., Frey J.M., Yingling J.E., Griffiths R.R. Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav. Pharmacol. 1997, 8:561-574.
36. Nordstrom B.R., Levin F.R. Treatment of cannabis use disorders: a review of the literature. Am. J. Addict. 2007, 16:331-342.
37. Patterson F., Jepson C., Strasser A.A., Loughead J., Perkins K.A., Gur R.C., Frey J.M., Siegel S., Lerman C. Varenicline improves mood and cognition during smoking abstinence. Biol. Psychiatry 2009, 65:144-149.
38. Perkins K.A., Mercincavage M., Fonte C.A., Lerman C. Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence. Psychopharmacology 2010, 210:45-51.
39. Pertwee The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: D9-tetrahydrocannabinol, cannabidiol and D9-tetrahydrocannabivarin. Br. J. Pharmacol. 2008, 153:199-215.
40. Ramaekers J.G., Kauert G., Van Ruitenbeek P., Theunissen E.L., Schneider E., Moeller M.R. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 2006, 31:2296-2303.
41. Raupach T., van Schayck C.P. Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs 2011, 25:371-382.
42. Reitan R.M., Wolfson E. The Halstead-Reitan Neuropsychological Test Battery 1985, Neuropsychology Press, Tuscon.
43. SAMHSA Treatment Episode Data Set (TEDS) 1995-2007: National Admissions to Substance Abuse Treatment Services 2008, US Department of Health and Human Services, Rockville, MD.
44. Shallice T. Specific impairments of planning. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 1982, 298:199-209.
45. Sobell L.C., Sobell M.B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods 1992, 41-72. Human Press, Totowa, NJ. J.P. Allen, R.Z. Litten (Eds.).
46. Stotts A.L., Dodrill C.L., Kosten T.R. Opioid dependence treatment: options in pharmacotherapy. Expert Opin. Pharmacother. 2009, 10:1727-1740.
47. UNODC World Drug Report - 2007. 2007, United Nations Office on Drugs and Crime, New York, NY.
48. Vandrey R., Haney M. Pharmacotherapy for cannabis dependence: how close are we?. CNS Drugs 2009, 23:543-553.
49. Vandrey R.G., Budney A.J., Hughes J.R., Liguori A. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances simultaneously. Drug Alcohol Depend. 2008, 92:48-54.
50. West R., Baker C.L., Cappelleri J.C., Bushmakin A.G. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 2008, 197:371-377.